Why the study?
Does the 100-μg dose of the SARS-CoV-2 mRNA-1273 vaccine improve immunogenicity compared to the 25-μg dose in older adults?
Does the 100-μg dose of the SARS-CoV-2 mRNA-1273 vaccine improve immunogenicity compared to the 25-μg dose in older adults?
The 100-μg dose of the mRNA-1273 vaccine is safe and more immunogenic than the 25-μg dose in older adults, supporting its use in phase 3 trials.
This is the authors' abstract. We don't add key points for this paper.
In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461.).
Answers are grounded in this paper and cite their sources.
Supports 100-μg dosing for phase 3 trials in older adults; extends dose-finding data for mRNA-1273.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: